8 October 2024 UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101.
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ABL Bio Corp on Friday revealed that it has entered into a clinical trial collaboration and supply agreement with MSD (the ex-US/Canada trading name of Merck & Co. 7 October 2024
BeiGene has launched Tevimbra (tislelizumab) in the USA for the treatment of certain adults with esophageal squamous cell carcinoma (ESCC), after chemo. 7 October 2024
Kezar Life Sciences has paused its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 7 October 2024
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
The International Vaccine Institute (IVI) has announced the first participant received Bharat Biotech International Ltd’s (BBIL) Chikungunya vaccine candidate (BBV87) in a Phase II/III clinical trial in Costa Rica. 25 August 2021
For spinal muscular atrophy (SMA) Awareness Month, we take a look at advances in the pharmacological treatment of this rare hereditary disease. 25 August 2021
Approval has been granted for the combination of Opdivo (nivolumab) intravenous infusion and Cabometyx (cabozantinib s-malate) tablets in Japan for the treatment of unresectable or metastatic renal cell carcinoma (RCC), for a partial change in approved items of the manufacturing and marketing approval. 25 August 2021
UK-based T cell receptor (TCR) biotech firm Immunocore yesterday announced that regulators in the USA and European Union have each accepted applications for the approval of tebentafusp (IMCgp100) for the treatment of HLA-A*02:01-positive adult patients with metastatic uveal melanoma (mUM). 25 August 2021
Children in England are set to be the first in the world to be offered direct acting antiviral (DAA) tablets for hepatitis C, as part of National Health Service (NHS) plans to eradicate the disease entirely. 24 August 2021
A host of companies have signed up to take part in Inno4Vac, a newly-established European public-private partnership to innovate vaccine development. 24 August 2021
Shares of Denmark’s biopharma company Orphazyme rose 12.4% to $5.63 on Monday, as it announced that positive results from a Phase II/III trial of arimoclomol, an investigational heat-shock protein amplifier, in Niemann-Pick disease type C (NPC) have been published in the peer-reviewed Journal of Inherited Metabolic Disease (JIMD). 24 August 2021
The European Medicines Agency’s human medicines committee (CHMP) has adopted recommendations that will increase manufacturing capacity and supply of two COVID-19 vaccines in the European Union. 24 August 2021
The UK government has agreed to purchase 35 million more doses of the Pfize/BioNTech COVID-19 vaccine, to be delivered from the second half of next year. 24 August 2021
Shares in Swiss pharma company Novartis were 1% lower by lunchtime on Tuesday following news of a setback for Kymriah (tisagenlecleucel), the first approved CAR-T cell therapy. 24 August 2021
Australia’s Therapeutic Goods Administration (TGA) has granted provisional determination to the local subsidiary of Swiss pharma giant Roche in relation to the combination therapy casirivimab + imdevimab, now trade-named Ronapreve. 24 August 2021
Norwegian clinical-stage biotech BerGenBio has announced the appointment of Martin Olin as its new chief executive, effective September 8, 2021. 24 August 2021
More than eight months after first being granted emergency use authorization (EUA), the COVID-19 vaccine from Pfizer and BioNTech has received full approval from the US Food and Drug Administration (FDA). 23 August 2021
French biotech Valneva has started rolling submission for initial approval of its COVID-19 vaccine candidate, VLA2001, with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). 23 August 2021
Sino-America biotech firm BeiGene today said that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental Biologics License Application (sBLA) for its anti-PD-1 antibody tislelizumab in combination with chemotherapy as a first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer (NPC). 23 August 2021
Shares of Canadian immuno-oncology drug developer Trillium Therapeutics skyrocketed 193% to $17.8 pre-market today, after it was revealed that its board has accepted a takeover bid from US pharma giant Pfizer. 23 August 2021
The US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) 240mg every two weeks or 480 mg every four weeks for the adjuvant treatment of urothelial carcinoma (UC) patients at high risk of recurrence after radical resection, regardless of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status. 23 August 2021
Positive 12-week results from the Phase III ADVANCE trial evaluating atogepant for the preventive treatment of migraine in adults who meet criteria for episodic migraine have been published in the prestigious New England Journal of Medicine (NEJM). 21 August 2021
AstraZeneca has announced positive top-line results from a key Phase III trial of its injectable antibody therapy for COVID-19, AZD7442. 21 August 2021
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.